[Animal Modeling]-The newly designed master protease inhibitor can inhibit neocoronavirus infection in vitro and in transgenic mouse models

  The new coronavirus SARS-CoV-2 caused the Coronavirus Disease (COVID-19) in 2019 and is currently rampant worldwide. Vaccines are an urgent need to control the pandemic. To date, no preventive treatment for coronavirus has been approved. There are several effective and widely used SARS-CoV-2 vaccines on the market, but the continuous emergence of virus variants, the destruction of vaccine distribution and the production of restricted vaccines, the vaccine is SARS-CoV. It is not clear that the spread of 2 can indeed be suppressed. Therefore, it is still important to develop new treatment methods and preventive measures.

  In a new study, researchers from West China Hospital of Sichuan University and Kunming Institute of Zoology, Chinese Academy of Sciences, were designed to destroy the major protease (Mpro) of the SARS-CoV-2 virus. Based on approved drugs, it has shown strong anti-SARS-CoV-2 virus activity in vitro and in transgenic mouse models. The relevant research results were published in the "Science Journal". Vaccines are an important tool in the fight against COVID-19, but the development of antiviral drugs is still a top priority, especially with the emergence of SARS-CoV-2 mutants, which may partially evade vaccines. The SARS-CoV-2 protein Mpro is a protease, which is necessary for the cleavage of polyproteins into functional viral proteins. This important function makes it an important drug discovery target.